mhn armodafinil (Nuvigil) Coverage Update

Coverage Criteria

Initial Therapy — Narcolepsy

Covered when ALL of the following are met for Narcolepsy (Initial Approval):

Narcolepsy initial: 1) Diagnosis of narcolepsy; 2) Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3) Age ≥ 17 years; 4) If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5) Failure of a 1‑month trial of one of the following generic central nervous system stimulant agents at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced: amphetamine, dextroamphetamine, or methylphenidate; 6) Dose does not exceed both: a) 250 mg per day; b) 1 tablet per day.

Prior authorization may be required for CNS stimulants; Illinois HIM step therapy exception per IL HB 5395 applies.

Initial Therapy — Obstructive Sleep Apnea

Covered when ALL of the following are met for Obstructive Sleep Apnea (Initial Approval):

OSA initial: 1) Diagnosis of obstructive sleep apnea (OSA); 2) Age ≥ 17 years; 3) Documented residual sleepiness despite compliant positive airway pressure therapy (e.g., CPAP, BiPAP) used as monotherapy; 4) Armodafinil (Nuvigil) is prescribed concurrently with continued use of positive airway pressure therapy (e.g., CPAP, BiPAP); 5) If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed both: a) 250 mg per day; b) 1 tablet per day.

Step therapy exception for Illinois HIM per IL HB 5395 noted in prior reviews; 2Q 2026 added/clarified concurrent PAP requirement.

Initial Therapy — Shift Work Disorder

Covered when ALL of the following are met for Shift Work Disorder (Initial Approval):

SWD initial: 1) Diagnosis of shift work disorder (SWD); 2) Age ≥ 17 years; 3) If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 4) Dose does not exceed both: a) 150 mg per day; b) 1 tablet per day.

Dosing guidance: single dose approximately 1 hour prior to start of work shift.

Initial Therapy — MS-associated fatigue (off-label)

Covered when ALL of the following are met for Multiple Sclerosis–associated fatigue (off‑label Initial Approval):

MS fatigue initial: 1) Diagnosis of MS‑associated fatigue; 2) Age ≥ 17 years; 3) Failure of 200 mg/day of amantadine and ≥ 10 mg/day of methylphenidate unless contraindicated or clinically significant adverse effects are experienced; 4) If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5) Dose does not exceed both: a) 250 mg per day; b) 1 tablet per day.

Illinois HIM step therapy exception per IL HB 5395 applies.

Continuation Therapy — All Indications

Continued therapy (all indications) — covered when ALL of the following are met:

Continued therapy general: 1) Member currently receiving medication via Centene benefit or member has previously met initial approval criteria OR member is in a continuity of care period; 2) Member is responding positively to therapy; 3) For OSA, armodafinil (Nuvigil) is prescribed concurrently with continued use of positive airway pressure therapy (e.g., CPAP, BiPAP); 4) If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5) If request is for a dose increase, new dose must not exceed indication‑specific maximums: a) Narcolepsy, OSA, and MS‑associated fatigue: 250 mg per day and 1 tablet per day; b) SWD: 150 mg per day and 1 tablet per day.

Approval durations typically 12 months; 2Q 2026 clarified OSA PAP requirement.

Non‑FDA approved indications that are not specifically addressed in this policy are excluded from coverage unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace/ICHRA), or CP.PMN.53 (Medicaid), or unless the indication is otherwise supported by the member’s evidence of coverage.

Armodafinil is contraindicated in patients with a known hypersensitivity to modafinil or armodafinil. Requests for therapy in members with documented hypersensitivity should be denied per this contraindication.

Initial Therapy

Initial Therapy — Initial authorization criteria by indication

Initial authorization criteria by indication

Initial by indication: See individual indication criteria for Narcolepsy, Obstructive Sleep Apnea, Shift Work Disorder, and Multiple Sclerosis–associated fatigue (off‑label) which include diagnosis, age ≥ 17 years, prescriber specialty where applicable, prior trial/step requirements, concurrent PAP use for OSA, brand‑to‑generic requirement unless contraindicated, and indication‑specific dose limits.

Prescribing information and clinical guidelines are referenced for these criteria.

Initial therapy — based on prescribing information and clinical guidelines

Initial therapy guidance is based on prescribing information and clinical guidelines referenced.

Guideline basis: Initial therapy criteria follow the Nuvigil (armodafinil) prescribing information and relevant clinical practice guidelines for narcolepsy, OSA, and circadian rhythm/shift work disorders.

References include Nuvigil prescribing information and AASM and guideline publications.

Continuation Therapy

Continuation Therapy — continuation therapy requirements

Continuation therapy requirements

Continuation requirements: 1) Member meets one of: currently receiving medication via Centene benefit or previously met initial approval criteria; or member is in an applicable continuity of care period; 2) Member is responding positively to therapy; 3) For OSA, armodafinil is prescribed concurrently with continued use of positive airway pressure therapy; 4) Brand‑to‑generic requirement applies unless contraindicated; 5) Dose increase requests must not exceed indication‑specific maximums (Narcolepsy/OSA/MS: 250 mg/day & 1 tablet/day; SWD: 150 mg/day & 1 tablet/day).

See approval durations in policy (typically 12 months).

Continuation therapy for OSA — updated in 2Q 2026

Continuation/ongoing therapy requirements updated in 2Q 2026

OSA continuation: For OSA, continued coverage requires that armodafinil is prescribed concurrently with ongoing use of positive airway pressure therapy (e.g., CPAP or BiPAP).

From 2Q 2026 annual review.

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required — provider must demonstrate indication-specific criteria including diagnosis, prescriber specialty, age, step-therapy trials, and dose limits. Requests for brand Nuvigil require trial of generic armodafinil unless contraindicated or adverse effects occur. For OSA, prior authorization also requires documentation of concurrent and continued positive airway pressure (e.g., CPAP, BiPAP) use. Failure to provide required documentation may result in denial.

Prior authorization required for initial and continued therapy per criteria in Section I and II.
If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced.

Documentation Required

Supporting Clinical Documentation

Provider must submit documentation (such as office chart notes, lab results, sleep study reports, CPAP/BiPAP compliance records, and consultant notes) supporting that the member has met all approval criteria. Lack of sufficient supporting clinical documentation or requests for non‑FDA indications without adequate off‑label justification may be denied.

Step Therapy and Therapeutic Alternatives

Step	Requirement
1	Trial of specified generic alternatives required unless contraindicated or clinically significant adverse effects occur: failure of a 1‑month trial of one of the following generic CNS stimulant agents at up to maximally indicated doses — amphetamine, dextroamphetamine, or methylphenidate (narcolepsy); for MS‑associated fatigue, failure of amantadine 200 mg/day and ≥10 mg/day methylphenidate is required.

Step

Requirement

Trial of specified generic alternatives required unless contraindicated or clinically significant adverse effects occur: failure of a 1‑month trial of one of the following generic CNS stimulant agents at up to maximally indicated doses — amphetamine, dextroamphetamine, or methylphenidate (narcolepsy); for MS‑associated fatigue, failure of amantadine 200 mg/day and ≥10 mg/day methylphenidate is required.

Jurisdiction / Line of Business	Step therapy exception / note
Illinois HIM	Step therapy requirement does not apply for Illinois HIM requests per IL HB 5395 (effective 1/1/2026); documented in policy updates and annual review notes.

Coding and Dosing Limits

Maximum dose

Maximum dose — Narcolepsy/OSA/MS-associated fatigue250 mg per day (and maximum 1 tablet/day)

Maximum dose — Shift Work Disorder (SWD)150 mg per day (and maximum 1 tablet/day)

Dose limits on dose increase (continuation)If dose increase requested, new dose must not exceed indication-specific maximums: Narcolepsy/OSA/MS = 250 mg/day; SWD = 150 mg/day

Quantity Limits

Armodafinil (Nuvigil) — quantity limits

Quantity limit — tablets per day1 tablet per day

ReasoningApproval criteria and quantity limits restrict to a single tablet daily across indications unless otherwise specified

Related product strengthsTablets available in 50, 150, 200, 250 mg

Armodafinil (Nuvigil) — quantity limit (mg)

Dose range (mg) — indication dependent150–250 mg per day depending on indication

SWD specific maximumSWD: 150 mg/day as single dose ≈1 hour prior to shift

Narcolepsy/OSA/MS maximum

Definitions and References

OSA — requirements

Definition — Obstructive Sleep Apnea (OSA)Excessive sleepiness due to OSA; medication for residual sleepiness must be prescribed concurrently with continued use of positive airway pressure therapy (e.g., CPAP, BiPAP)

Age requirementAge ≥ 17 years for covered OSA indication

Documentation requiredDocumented evidence of residual sleepiness despite compliant positive airway pressure therapy is required

SWD — dosing guidance

Definition — Shift Work Disorder (SWD)Sleep disorder related to shift work; covered for adults with dose guidance

Dosing guidanceSingle dose of 150 mg once daily approximately 1 hour prior to the start of the work shift

Background

Armodafinil (Nuvigil) is a wakefulness‑promoting agent indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as residual sleepiness despite positive airway pressure therapy), and shift work disorder. It is also considered for a limited off‑label indication—fatigue associated with multiple sclerosis—only when required prior trials and documentation are met. The product has no reported boxed warnings, but use is contraindicated in individuals with a known hypersensitivity to modafinil or armodafinil.

Revision History

2026-03-26policy_updateLatest

Added requirement that for OSA armodafinil (Nuvigil) must be prescribed concurrently with continued use of positive airway pressure therapy and broadened CPAP language to allow any positive airway pressure therapy (e.g., BiPAP); references reviewed and updated; ICHRA line of business added.

2025-04-07policy_note

Added step therapy bypass for Illinois HIM per IL HB 5395 during 2Q 2025 annual review; references reviewed and updated.

2024-01-12

OpenPayer

Clinical Policy: Armodafinil (Nuvigil)